The introduction of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, which enable a reduction in low-density lipoprotein cholesterol (LDL-C) to levels previously unattainable with statin therapy, has established the principle of “the lower, the better” as the prevailing approach for LDL-C lowering in the prevention of atherosclerotic cardiovascular disease (ASCVD) [8]. Here, PCSK9 is linked to atherosclerosis.